Open Access

Poster session 2 - Stable angina - Treatment and outcomes

Event: ESC CONGRESS 2016
Topic: Miscellaneous
Session type: Poster Session
Date: 28 August 2016

Session

24 presentations in this session

Statins for the prevention of early postoperative cognitive dysfunction in patients undergoing coronary artery bypass grafting

Speaker: Doctor O. Maleva (Kemerovo, RU)
Thumbnail

Temporal trends in management and long-term prognosis of patients with stable angina between 2006 and 2012

Speaker: Professor M. Gasior (Zabrze, PL)
Thumbnail

Early vascular responses to everolimus-eluting cobalt-chromium stent for the treatment of stable coronary artery disease: The results of MECHANISM-Elective 1 and 3 months OCT follow-up cohort

Speaker: Professor T. Shinke (Tokyo, JP)
Thumbnail

In stable patients with suspected coronary artery disease the concentrations of high sensitive troponin I are related to the clinical angina classification

Speaker: Miss D. Madsen (Odense, DK)
Thumbnail

Five-year clinical outcomes in patients with moderate coronary artery spasm as assessed by intracoronary acetylcholine provocation test

Speaker: Professor Y. Kim (Chuncheon, KR)
Thumbnail

Bioabsorbable scaffolds for patients with diabetes mellitus

Thumbnail

Women with microvascular coronary dysfunction have different risk factors, more symptoms and less quality of life than women with stable obstructive coronary artery disease

Speaker: Doctor S. Elias-Smale (Nijmegen, NL)
Thumbnail

Clinical acceptability of trimetazidine 80 mg once daily versus trimetazidine modified release 35 mg twice daily in chronic stable angina pectoris

Speaker: Professor Y. Pozdnyakov (Zhukovsky, RU)
Thumbnail

Trends in the interventional treatment of patients with stable coronary artery disease in clinical practice. Results from the ALKK PCI Registry.

Speaker: Doctor N. Werner (Offenbach, DE)
Thumbnail

The impact of crack pattern and calcified nodule before stenting estimated by optical coherence tomography on stent expansion at severe calified lesion

Speaker: Doctor H. Shibata (Osaka, JP)
Thumbnail

22 speakers from this session

Doctor Olga Maleva

Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo (Russian Federation)
0 follower

Professor Mariusz Gasior

, Zabrze (Poland)
0 follower

Professor Toshiro Shinke

Showa University, Tokyo (Japan)
0 follower

Miss Debbie Maria Madsen

Odense University Hospital, Odense (Denmark)
0 follower

Professor Yong Hoon Kim

Kangwon National University School of Medicine, Chuncheon (Korea (Republic of))
0 follower

Doctor Suzette Elias-Smale

Radboud University Medical Centre, Nijmegen (Netherlands (The))
2 presentations
0 follower

Professor Yuri Pozdnyakov

Moscow Regional Cardiology Center, Zhukovsky (Russian Federation)
0 follower

Doctor Nicolas Werner

Sana Clinic Offenbach, Offenbach (Germany)
0 follower

Doctor Hiroyuki Shibata

Osaka Saiseikai Nakatsu Hospital, Osaka (Japan)
0 follower

Doctor Hiroyuki Yamamoto

Kobe University, Kobe (Japan)
0 follower

Doctor Stanislav Keranov

University Hospital Giessen And Marburg, Giessen (Germany)
0 follower

Doctor Ekaterina Gofman

National Research Center for Preventive Medicine, Moscow (Russian Federation)
0 follower

Doctor Stefano Cornara

San Paolo Hospital, Savona (Italy)
0 follower

Doctor Masahito Kajiya

, Niihama (Japan)
0 follower

Doctor Hunain Shiwani

University College London, London (United Kingdom of Great Britain & Northern Ireland)
0 follower

Doctor Rayna Tasheva

Second MHAT, Sofia (Bulgaria)
0 follower

Ms Ingrid Bank

University Medical Center Utrecht, Utrecht (Netherlands (The))
0 follower

Doctor Dariusz Slawek

Bieganski Hospital, Lodz (Poland)
0 follower

Doctor Takayuki Ohwada

Fukusima red cross hospital, Fukushima city (Japan)
0 follower

Doctor Shinichiro Sakurai

Aichi Medical University, Nagakute (Japan)
0 follower

Doctor Joao Carmo

Hospital de Santa Cruz, Carnaxide (Portugal)
0 follower

Ms Aneta Cislak

Silesian Center for Heart Diseases (SCHD), Zabrze (Poland)
0 follower

This platform is supported by

logo Novo Nordisk